Cargando…

Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma

Detalles Bibliográficos
Autores principales: Ashoor, Arwa, Shephard, Julie, Lissidini, Germana, Nicosia, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Radiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240295/
https://www.ncbi.nlm.nih.gov/pubmed/35695318
http://dx.doi.org/10.3348/kjr.2022.0207
_version_ 1784737507584245760
author Ashoor, Arwa
Shephard, Julie
Lissidini, Germana
Nicosia, Luca
author_facet Ashoor, Arwa
Shephard, Julie
Lissidini, Germana
Nicosia, Luca
author_sort Ashoor, Arwa
collection PubMed
description
format Online
Article
Text
id pubmed-9240295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Radiology
record_format MEDLINE/PubMed
spelling pubmed-92402952022-07-07 Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma Ashoor, Arwa Shephard, Julie Lissidini, Germana Nicosia, Luca Korean J Radiol Letter to the Editor The Korean Society of Radiology 2022-07 2022-05-31 /pmc/articles/PMC9240295/ /pubmed/35695318 http://dx.doi.org/10.3348/kjr.2022.0207 Text en Copyright © 2022 The Korean Society of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Ashoor, Arwa
Shephard, Julie
Lissidini, Germana
Nicosia, Luca
Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
title Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
title_full Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
title_fullStr Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
title_full_unstemmed Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
title_short Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
title_sort response to letter; discrimination between benign and malignant post-sars-cov-2 vaccination lymphadenopathy is feasible, to our article; axillary adenopathy in patients with recent covid-19 vaccination: a new diagnostic dilemma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240295/
https://www.ncbi.nlm.nih.gov/pubmed/35695318
http://dx.doi.org/10.3348/kjr.2022.0207
work_keys_str_mv AT ashoorarwa responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma
AT shephardjulie responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma
AT lissidinigermana responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma
AT nicosialuca responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma